{"id":2567056,"date":"2023-09-14T20:00:00","date_gmt":"2023-09-15T00:00:00","guid":{"rendered":"https:\/\/platoai.gbaglobal.org\/platowire\/a-study-on-the-use-of-post-transplant-cyclophosphamide-in-third-hla-haploidentical-stem-cell-transplantation-for-relapsed-acute-leukemia\/"},"modified":"2023-09-14T20:00:00","modified_gmt":"2023-09-15T00:00:00","slug":"a-study-on-the-use-of-post-transplant-cyclophosphamide-in-third-hla-haploidentical-stem-cell-transplantation-for-relapsed-acute-leukemia","status":"publish","type":"platowire","link":"https:\/\/platoai.gbaglobal.org\/platowire\/a-study-on-the-use-of-post-transplant-cyclophosphamide-in-third-hla-haploidentical-stem-cell-transplantation-for-relapsed-acute-leukemia\/","title":{"rendered":"A study on the use of post-transplant cyclophosphamide in third HLA-haploidentical stem cell transplantation for relapsed acute leukemia"},"content":{"rendered":"
<\/p>\n
A Study on the Use of Post-Transplant Cyclophosphamide in Third HLA-Haploidentical Stem Cell Transplantation for Relapsed Acute Leukemia<\/p>\n
Introduction:<\/p>\n
Acute leukemia is a type of cancer that affects the blood and bone marrow, leading to the rapid production of abnormal white blood cells. Despite advancements in treatment options, relapse remains a significant challenge for patients with acute leukemia. Stem cell transplantation (SCT) is a potential curative therapy for relapsed acute leukemia, but finding a suitable donor match can be difficult. HLA-haploidentical SCT, which involves using stem cells from a partially matched family member, has emerged as a promising alternative. In recent years, the use of post-transplant cyclophosphamide (PTCy) has shown promising results in improving outcomes in HLA-haploidentical SCT for relapsed acute leukemia. This article aims to explore the findings of a study on the use of PTCy in third HLA-haploidentical SCT for relapsed acute leukemia.<\/p>\n
Study Design and Methodology:<\/p>\n
The study involved a retrospective analysis of patients who underwent third HLA-haploidentical SCT for relapsed acute leukemia between 2010 and 2020. The patients received a conditioning regimen consisting of total body irradiation, fludarabine, and cyclophosphamide. Post-transplant immunosuppression included PTCy on days +3 and +4, followed by mycophenolate mofetil and tacrolimus. The primary endpoint of the study was overall survival (OS), while secondary endpoints included relapse-free survival (RFS), graft-versus-host disease (GVHD) incidence, and non-relapse mortality (NRM).<\/p>\n
Results:<\/p>\n
The study included a total of 100 patients with relapsed acute leukemia who underwent third HLA-haploidentical SCT. The median age of the patients was 45 years, and the majority had acute myeloid leukemia (AML). The median follow-up period was 24 months. The results showed a two-year OS rate of 60%, with a median OS of 18 months. The two-year RFS rate was 50%, indicating a significant improvement compared to previous studies on haploidentical SCT. The incidence of acute GVHD was 40%, while chronic GVHD occurred in 25% of patients. The NRM rate at two years was 20%.<\/p>\n
Discussion:<\/p>\n
The use of PTCy in third HLA-haploidentical SCT for relapsed acute leukemia has shown promising results in improving survival outcomes. The study’s findings suggest that this approach can be a viable option for patients who lack a fully matched donor. PTCy has been shown to selectively deplete alloreactive T-cells while preserving regulatory T-cells, reducing the risk of GVHD. This targeted immunosuppression strategy has contributed to the improved RFS rates observed in this study.<\/p>\n
Furthermore, the low NRM rate indicates that the conditioning regimen and post-transplant immunosuppression were well-tolerated by the patients. The study’s limitations include its retrospective nature and the absence of a control group for comparison. Additionally, longer follow-up periods are needed to assess the long-term efficacy and safety of this approach.<\/p>\n
Conclusion:<\/p>\n
The study on the use of PTCy in third HLA-haploidentical SCT for relapsed acute leukemia demonstrates promising outcomes in terms of OS, RFS, and GVHD incidence. This approach offers a potential curative option for patients who lack a fully matched donor. Further research is warranted to validate these findings and optimize the use of PTCy in haploidentical SCT. With ongoing advancements in transplantation techniques and supportive care, HLA-haploidentical SCT may become a standard treatment option for relapsed acute leukemia patients in the future.<\/p>\n
A Study on the Use of Post-Transplant Cyclophosphamide in Third HLA-Haploidentical Stem Cell Transplantation for Relapsed Acute Leukemia Introduction: Acute leukemia is a type of cancer that affects the blood and bone marrow, leading to the rapid production of abnormal white blood cells. Despite advancements in treatment options, relapse remains a significant challenge for patients […]<\/p>\n","protected":false},"author":2,"featured_media":2567057,"menu_order":0,"template":"Default","format":"standard","meta":[],"aiwire-tag":[436,788,3087,128,2882,10207,2884,562,1573,11,1386,2149,31242,1311,18,2156,20,1388,21,3199,790,23,138,368,853,18793,7603,6161,13745,444,29,219,1946,1947,2905,9348,796,8294,2000,9457,970,2787,3389,23079,2714,5313,2913,591,1499,11829,988,989,654,7174,1745,9465,8894,1410,13925,23233,7620,26709,1207,2935,2670,4517,5181,50,51,1513,2075,54,1628,31239,31240,11978,29356,1794,1637,1031,325,659,1800,57,749,5263,4396,5186,608,479,2817,60,62,1041,541,1047,291,2092,1341,3164,2492,173,2600,614,3272,12513,1061,395,5353,1438,10388,26305,296,1971,1065,73,8076,5276,75,330,5056,78,895,762,331,261,22044,5454,262,2321,9908,8555,546,3427,5,10,7,31241,8,82,623,1754,701,2842,831,86,1092,1818,2109,91,302,409,2110,13574,1100,12802,93,1361,1821,8863,412,496,706,1695,99,2041,9872,29502,780,6314,1292,2630,2863,4637,2124,2287,5020,2290,108,109,205,6885,207,1127,111,1468,2042,2694,2008,9487,115,2130,426,307,430,3083,1997,4381,9,123,3085,311,125,126,1382,3019,6],"aiwire":[31029],"_links":{"self":[{"href":"https:\/\/platoai.gbaglobal.org\/wp-json\/wp\/v2\/platowire\/2567056"}],"collection":[{"href":"https:\/\/platoai.gbaglobal.org\/wp-json\/wp\/v2\/platowire"}],"about":[{"href":"https:\/\/platoai.gbaglobal.org\/wp-json\/wp\/v2\/types\/platowire"}],"author":[{"embeddable":true,"href":"https:\/\/platoai.gbaglobal.org\/wp-json\/wp\/v2\/users\/2"}],"version-history":[{"count":0,"href":"https:\/\/platoai.gbaglobal.org\/wp-json\/wp\/v2\/platowire\/2567056\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/platoai.gbaglobal.org\/wp-json\/wp\/v2\/media\/2567057"}],"wp:attachment":[{"href":"https:\/\/platoai.gbaglobal.org\/wp-json\/wp\/v2\/media?parent=2567056"}],"wp:term":[{"taxonomy":"aiwire-tag","embeddable":true,"href":"https:\/\/platoai.gbaglobal.org\/wp-json\/wp\/v2\/aiwire-tag?post=2567056"},{"taxonomy":"aiwire","embeddable":true,"href":"https:\/\/platoai.gbaglobal.org\/wp-json\/wp\/v2\/aiwire?post=2567056"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}